首页> 外文期刊>Protein engineering design & selection: PEDS >Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization
【24h】

Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization

机译:癌症相关的MyD88-TIR结构域突变体L252P(L265P)的构象动力学使地貌向同二聚体倾斜

获取原文
获取原文并翻译 | 示例
           

摘要

MyD88 is an essential adaptor protein, which mediates the signaling of the toll-like and interleukin-1 receptors' superfamily. The MyD88 L252P (L265P) mutation has been identified in diffuse large B-cell lymphoma. The identification of this mutation has been a major advance in the diagnosis of patients with aldenstrom macroglobulinemia and related lymphoid neoplasms. Here we used computational methods to characterize the conformational effects of the mutation. Our molecular dynamics simulations revealed that the mutation allosterically quenched the global conformational dynamics of the toll/IL-1R (TIR) domain, and readjusted its salt bridges and dynamic community network. Specifically, the mutation changed the orientation and reduced the fluctuation of a-helix 3, possibly through eliminating/weakening similar to 8 salt bridges and enhancing the salt bridge D225-K258. Using the energy landscape of the TIR domains of MyD88, we identified two dynamic conformational basins, which correspond to the binding sites used in homo- and hetero-oligomerization, respectively. Our results indicate that the mutation stabilizes the core of the homo-dimer interface of the MyD88-TIR domain, and increases the population of homo-dimer-compatible conformational states in MyD88 family proteins. However, the dampened motion restricts its ability to heterodimerize with other TIR domains, thereby curtailing physiological signaling. In conclusion, the L252P both shifts the landscape toward homo-dimerization and restrains the dynamics of the MyD88-TIR domain, which disfavors its hetero-dimerization with other TIR domains. We further put these observations within the framework of MyD88-mediated cell signaling.
机译:MyD88是必不可少的衔接蛋白,它介导Toll样和白介素1受体超家族的信号传导。 MyD88 L252P(L265P)突变已在弥漫性大B细胞淋巴瘤中发现。该突变的鉴定已成为诊断患有aldenstrom巨球蛋白血症和相关淋巴瘤的患者的重大进展。在这里,我们使用计算方法来表征突变的构象效应。我们的分子动力学模拟显示该突变变构地终止了toll / IL-1R(TIR)域的整体构象动力学,并重新调整了其盐桥和动态社区网络。具体而言,该突变改变了方向并减少了α-螺旋3的波动,这可能是通过消除/减弱类似于8个盐桥并增强盐桥D225-K258来实现的。使用MyD88的TIR域的能量分布图,我们确定了两个动态构象盆地,分别对应于均聚和异聚的结合位点。我们的结果表明,该突变稳定了MyD88-TIR域的同二聚体界面的核心,并增加了MyD88家族蛋白中同二聚体相容的构象态的种群。但是,受抑制的运动限制了其与其他TIR域异二聚化的能力,从而减少了生理信号传导。总而言之,L252P不仅使格局向均二聚化转变,而且还限制了MyD88-TIR域的动力学,这不利于MyD88-TIR域与其他TIR域的异源二聚化。我们进一步将这些观察结果放在MyD88介导的细胞信号转导框架内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号